3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
76
Neoplasm Metastasis
12
Neoplasms
10
Neoplasms by Site
4
Advanced Breast Cancer
4
Squamous Cell Carcinoma of Head and Neck
3
Ovarian Neoplasms
3
Hereditary Sensory and Autonomic Neuropathies
3
Head and Neck Neoplasms
3
Carcinoma, Renal Cell
3
Breast Diseases
3
Recurrence
2
Kidney Neoplasms
2
Endometrial Neoplasms
2
Digestive System Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Advanced Solid Tumors
2
von Hippel-Lindau Disease
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Unilateral Breast Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Skin Diseases
1
Sarcoma, Ewing
1
Sarcoma
1
Interventions
Bevacizumab
9
Oxaliplatin
7
Irinotecan
6
Fluorouracil
6
Nivolumab
5
Leucovorin
5
Cetuximab
5
Capecitabine
5
pembrolizumab
4
Sunitinib
4
IFL protocol
4
Drug Therapy
4
Cisplatin
4
encorafenib
3
Pemetrexed
3
Gemcitabine
3
Folfox protocol
3
5,10-methylenetetrahydrofolic acid
3
trebananib
2
trastuzumab deruxtecan
2
amminedichloro(2-methylpyridine)platinum(II)
2
Ocoxin
2
N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
2
Levoleucovorin
2
IDRX-42
2
CGX1321
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
ulixertinib
1
tivozanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Gastrointestinal Neoplasms
×
palbociclib
×
Clear all
NCT05039177
2026-03-25
HERKULES-3
Erasca, Inc.
Phase 1/2
Completed
101 enrolled